Zentalis Pharmaceuticals, Inc.
0.85xPrice / book
Market cap
$285.97M
Tangible equity
—
Price / tangible book
—
Price / book
0.85x
Return on equity
-49.2%
Return on assets
-38.5%
Efficiency ratio
—
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ZNTL stock price vs DFS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DFS's multiple
Needs DFS P/B.
Implied fair value · at ZNTL's multiple
Metric by metric
Price unavailable
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Profitability lag
Asset efficiency lag
Lower is better
Statements
Bank-focused income statement and equity metrics aligned to the reporting windows.
SEC periods: ZNTL FY 2024 (ended Dec 31, 2024) · DFS FY 2024 (ended Dec 31, 2024).
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
$285.97M
Tangible equity
—
Price / tangible book
—
Price / book
0.85x
Return on equity
-49.2%
Return on assets
-38.5%
Efficiency ratio
—
Price / book
Market cap
—
Tangible equity
$17.67B
Price / tangible book
—
Price / book
—
Return on equity
25.3%
Return on assets
3.1%
Efficiency ratio
29.3%
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Zentalis Pharmaceuticals, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
DISCOVER FINANCIAL SERVICES · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.24x
0.91x
Net debt / EBITDA
Leverage against operating earnings
-0.29x
-0.57x
Cash and equivalents
Liquid reserves on the balance sheet
$33.90M
$23.10B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Arcus Biosciences, Inc.
ZNTL vs RCUS
Repare Therapeutics Inc.
ZNTL vs RPTX
IDEAYA Biosciences, Inc.
ZNTL vs IDYA
Mersana Therapeutics, Inc.
ZNTL vs MRSN
EXELIXIS, INC.
ZNTL vs EXEL
CAPITAL ONE FINANCIAL CORP
ZNTL vs COF
American Express Company
ZNTL vs AXP
Visa Inc.
ZNTL vs V
Mastercard Incorporated
ZNTL vs MA
$82.57M
$16.25B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.